top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Michael Halstead Biography and Net Worth

EVP of Intra-Cellular Therapies

Mr. Halstead has been the General Counsel of ITCI since July 2014. From July 2005 until December 2013, Mr. Halstead served in a number of leadership positions at Warner Chilcott plc, a leading specialty pharmaceutical company that was acquired by Actavis plc in October 2013. Most recently, he was Senior Vice President, Corporate Development at Warner Chilcott, where he directed the company’s corporate development, legal, and human resources functions. Prior to that, Mr. Halstead was an attorney at Davis Polk & Wardwell, where he focused his practice on mergers and acquisitions, corporate governance, and securities law compliance.

Mr. Halstead received his bachelor’s degree from Boston University and his Juris Doctor degree from Villanova University School of Law.

What is Michael Halstead's net worth?: The estimated net worth of Michael Halstead is at least $1.47 million as of March 11th, 2024. Mr. Halstead owns 19,803 shares of Intra-Cellular Therapies stock worth more than $1,465,620 as of April 23rd. This net worth estimate does not reflect any other investments that Mr. Halstead may own. Additionally, Mr. Halstead receives a salary of $983,650.00 as EVP at Intra-Cellular Therapies. Learn More about Michael Halstead's net worth.
How old is Michael Halstead?: Mr. Halstead is currently 51 years old. There are 6 older executives and no younger executives at Intra-Cellular Therapies. The oldest executive at Intra-Cellular Therapies is Dr. Robert E. Davis Ph.D., Senior VP & Chief Scientific Officer, who is 73 years old. Learn More on Michael Halstead's age.
What is Michael Halstead's salary?: As the EVP of Intra-Cellular Therapies, Inc., Mr. Halstead earns $983,650.00 per year. There are 2 executives that earn more than Mr. Halstead. The highest earning executive at Intra-Cellular Therapies is Dr. Sharon Mates Ph.D., Co-Founder, Chairman & CEO, who commands a salary of $2,230,000.00 per year. Learn More on Michael Halstead's salary.
How do I contact Michael Halstead?: The corporate mailing address for Mr. Halstead and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Michael Halstead's contact information.
Has Michael Halstead been buying or selling shares of Intra-Cellular Therapies?: Michael Halstead has not been actively trading shares of Intra-Cellular Therapies during the last quarter. Most recently, Michael Halstead sold 7,345 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.97, for a transaction totalling $484,549.65. Following the completion of the sale, the executive vice president now directly owns 19,803 shares of the company's stock, valued at $1,306,403.91. Learn More on Michael Halstead's trading history.
Who are Intra-Cellular Therapies' active insiders?: Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.
Are insiders buying or selling shares of Intra-Cellular Therapies?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 682,285 shares worth more than $43,934,823.19. The most recent insider tranaction occured on March, 11th when CEO Sharon Mates sold 20,565 shares worth more than $1,341,043.65. Insiders at Intra-Cellular Therapies own 3.4% of the company. Learn More about insider trades at Intra-Cellular Therapies.
Information on this page was last updated on 3/11/2024.

Michael Halstead Insider Trading History at Intra-Cellular Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	7,345	$65.97	$484,549.65	19,803
2/26/2024	Sell	7,907	$69.53	$549,773.71	29,700
1/11/2024	Sell	50,000	$66.83	$3,341,500.00
12/1/2022	Sell	50,000	$53.73	$2,686,500.00
12/21/2021	Sell	176,863	$47.56	$8,411,604.28
1/4/2021	Sell	16,160	$31.30	$505,808.00
11/17/2020	Sell	79,425	$27.62	$2,193,718.50	79,425
1/6/2020	Sell	21,458	$30.34	$651,035.72	17,704
1/2/2020	Sell	7,807	$32.43	$253,181.01	7,998
1/7/2019	Sell	3,108	$12.42	$38,601.36	24,757
1/4/2019	Sell	21,458	$11.46	$245,908.68	24,757
1/22/2018	Sell	25,500	$18.03	$459,765.00	191
1/5/2017	Sell	1,601	$16.55	$26,496.55	21,506
11/6/2014	Buy	20,000	$15.38	$307,600.00

Michael Halstead Buying and Selling Activity at Intra-Cellular Therapies

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $74.01

$73.69

$76.89

50 Day Range

MA: $69.41

$64.37

$79.84

2 Week Range

Now: $74.01

$45.50

$84.89

Volume

826,594 shs

Average Volume

949,397 shs

Market Capitalization

$7.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Michael Halstead Biography and Net Worth

What is Michael Halstead's net worth?

How old is Michael Halstead?

What is Michael Halstead's salary?

How do I contact Michael Halstead?

Has Michael Halstead been buying or selling shares of Intra-Cellular Therapies?

Who are Intra-Cellular Therapies' active insiders?

Are insiders buying or selling shares of Intra-Cellular Therapies?